V5P Stock Overview
Develops, produces, and sells active ingredients from plant stem cells for the cosmetic sector primarily in Spain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vytrus Biotech, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.16 |
| 52 Week High | €2.80 |
| 52 Week Low | €2.02 |
| Beta | -0.024 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| V5P | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | -2.0% |
| 1Y | 0% | -7.7% | 6.9% |
Return vs Industry: V5P underperformed the German Personal Products industry which returned 4.7% over the past year.
Return vs Market: V5P underperformed the German Market which returned 19.6% over the past year.
Price Volatility
| V5P volatility | |
|---|---|
| V5P Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 3.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V5P's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine V5P's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 35 | Albert Font | www.vytrus.com |
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells for the cosmetic sector primarily in Spain. It offers Nectaria Lithops, an active ingredient that biophysically optimizes the skin microenvironment and vitamin D levels; Photobiome a microbiota photoprotector; Olea Vitae cellular oil for ageing; Turmeria Zen for skin hydration and wrinkles on stressed profiles; Sensia Carota, a plant-based active that protects and prevents from the damage on sensitive and sensitized skins; Deobiome Noni, a biological deodorant; and Sarcoslim Re-Shape to reduce fat on tissue. The company also offers Capilia Longa for hair growth reactivation; Luminia Granatum for skin brightening;Elaya Renova a hair tensegrist; Kannabia Sense that stimulates the microbiota-skin-brain axis; Quora Noni to avoid the attack of skin harmful bacteria; Quora Noni biomics for rejuvenating the skin microbiota; Centella Reversa for facial complexion improvement; and Arabian Cotton for protection against photo-ageing.
Vytrus Biotech, S.A. Fundamentals Summary
| V5P fundamental statistics | |
|---|---|
| Market cap | €16.74m |
| Earnings (TTM) | €696.78k |
| Revenue (TTM) | €5.24m |
24.0x
P/E Ratio3.2x
P/S RatioIs V5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V5P income statement (TTM) | |
|---|---|
| Revenue | €5.24m |
| Cost of Revenue | €491.63k |
| Gross Profit | €4.75m |
| Other Expenses | €4.05m |
| Earnings | €696.78k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.092 |
| Gross Margin | 90.61% |
| Net Profit Margin | 13.30% |
| Debt/Equity Ratio | 29.8% |
How did V5P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/30 13:54 |
| End of Day Share Price | 2024/08/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vytrus Biotech, S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marisa Luisa Mazo Fajardo | GVC Gaesco Valores |